Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Nam Atiqur Rahman"'
Autor:
Olga Marchenko, Rajeshwari Sridhara, Qi Jiang, Elizabeth Barksdale, Yuki Ando, Dinesh De Alwis, Katie Brown, Laura Fernandes, Mark T. J. van Bussel, Qiuyi Choo, Michael Coory, Elizabeth Garrett-Mayer, Thomas Gwise, Lorenzo Hess, Rong Liu, Sumithra Mandrekar, Daniele Ouellet, José Pinheiro, Martin Posch, Nam Atiqur Rahman, Khadija Rerhou Rantell, Andrew Raven, Sarem Sarem, Suman Sen, Mirat Shah, Yuan Li Shen, Richard Simon, Marc Theoret, Ying Yuan, Richard Pazdur
Publikováno v:
Statistics in Biopharmaceutical Research. :1-7
Autor:
Asma Dilawari, Mirat Shah, Gwynn Ison, Haley Gittleman, Mallorie H. Fiero, Ankit Shah, Salaheldin S. Hamed, Junshan Qiu, Jingyu Yu, Wimolnut Manheng, Tiffany K. Ricks, Rajan Pragani, Arulvathani Arudchandran, Paresma Patel, Shadia Zaman, Arpita Roy, Shyam Kalavar, Soma Ghosh, William F. Pierce, Nam Atiqur. Rahman, Shenghui Tang, Bronwyn D. Mixter, Paul G. Kluetz, Richard Pazdur, Laleh Amiri-Kordestani
Publikováno v:
Clinical Cancer Research.
On November 14, 2022, the U.S. Food and Drug Administration (FDA) granted accelerated approval to mirvetuximab soravtansine-gynx for treatment of adult patients with folate receptor-α (FRα)-positive, platinum-resistant epithelial ovarian, fallopian
Autor:
Elizabeth S. Duke, Amy K. Barone, Somak Chatterjee, Pallavi S. Mishra-Kalyani, Yuan-Li Shen, Emasenyie Isikwei, Hong Zhao, Youwei Bi, Jiang Liu, Nam Atiqur Rahman, Emily Wearne, John K. Leighton, Maritsa Stephenson, Idara Ojofeitimi, Barbara Scepura, Abhilasha Nair, Richard Pazdur, Julia A. Beaver, Harpreet Singh
Publikováno v:
Clin Cancer Res
On September 17, 2021, the U.S. Food and Drug Administration (FDA) approved cabozantinib (Cabometyx™; Exelixis, Inc.) for the treatment of adult and pediatric patients 12 years of age and older with locally advanced or metastatic differentiated thy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9c0ec5bde23f247a822bb3ecd816099e
https://europepmc.org/articles/PMC9529996/
https://europepmc.org/articles/PMC9529996/
Autor:
Soma Ghosh, Willie Wilson, Pengfei Song, Laleh Amiri-Kordestani, Sherry Hou, Junshan Qiu, Hui Zhang, Richard Pazdur, Jeffrey D. Seidman, Julia A. Beaver, Reena Philip, Fatima Rizvi, Jennifer J Gao, Abde M. Abukhdeir, Vishal Bhatnagar, Yutao Gong, Haw-Jyh Chiu, Tiffany K. Ricks, Nam Atiqur Rahman, Paul G. Kluetz, William F. Pierce, Erik Bloomquist, Christy L. Osgood, Xiling Jiang, Jingyu Yu
Publikováno v:
Clinical Cancer Research. 27:2126-2129
On June 29, 2020, the FDA approved pertuzumab, trastuzumab, and hyaluronidase-zzxf subcutaneous injection (Phesgo) for the treatment of patients with HER2-positive early-stage and metastatic breast cancer. Patients should be selected for therapy base
Broadening Eligibility Criteria for Oncology Clinical Trials: Current Advances and Future Directions
Publikováno v:
Clinical pharmacology and therapeutics. 108(3)
Autor:
Nam Atiqur Rahman, Lian Ma, Janice Schwartz, Shuai Hu, Liang Li, Qi Liu, Gideon M. Blumenthal, Yaning Wang, Brian Booth, Hao Zhu
Publikováno v:
Cancer Research. 80:587-587
BACKGROUND: Renal impairment (RI) is a common complication in patients with multiple myeloma (MM). Effective myeloma treatment can lead to reduction in urinary light-chain excretion and reversibility of RI. Our pooled analysis assessed the magnitude
Autor:
Albert Deisseroth, Nam Atiqur Rahman, Ann T. Farrell, Vikram Sinha, Yaning Wang, Liang Li, Anshu Marathe, Lian Ma, Sarah J. Schrieber
Publikováno v:
Clinical pharmacology and therapeutics. 104(4)
The aim of the study was to evaluate the quantitative relationship between duration of severe neutropenia (DSN, the efficacy endpoint) and area under effect curve of absolute neutrophil counts (ANC-AUEC, the pharmacodynamic endpoint), based on data f
Autor:
Nam Atiqur Rahman, Ramana S. Uppoor, B. Nhi Beasley, Raman K. Baweja, Patrick J. Marroum, Chandrahas G. Sahajwalla, Veneeta Tandon, Roshni Ramchandani, Brian Booth, Venkatesh A. Bhattaram, J. Robert Powell, John Duan, Jogarao V. S. Gobburu, Mehul Mehta, Yaning Wang
Publikováno v:
The AAPS Journal. 7:E503-E512
The value of quantitative thinking in drug development and regulatory review is increasingly being appreciated. Modeling and simulation of data pertaining to pharmacokinetic, pharmacodynamic, and disease progression is often referred to as the pharma
Autor:
Stacy Shifflett Shord, Liang Zhao, Denise Casey, Nam Atiqur Rahman, Ping Zhao, Hong Zhao, Brian Booth, Patricia Keegan, Suzanne Demko
Publikováno v:
Journal of Clinical Oncology. 34:e14121-e14121
e14121Background: On July 24, 2015, FDA approved Odomzo (sonidegib) for the treatment of patients with locally advanced basal cell carcinoma. At the recommended dose of 200mg once daily, 68% of pat...
Autor:
T. C. Wu, Nam Atiqur Rahman, S. S. Brar, Lei Zhang, Lawrence J. Lesko, Rajnikanth Madabushi, Qi Liu, P. Song, Y. J. Moon, Brian Booth, Joseph A. Grillo, Huang Sm, E Gil Berglund, Kellie S. Reynolds, Ping Zhao, Julie Bullock
Publikováno v:
Clinical pharmacology and therapeutics. 89(2)
Physiologically based pharmacokinetic (PBPK) modeling and simulation is a tool that can help predict the pharmacokinetics of drugs in humans and evaluate the effects of intrinsic (e.g., organ dysfunction, age, genetics) and extrinsic (e.g., drug-drug